megestrol acetate has been researched along with Invasiveness, Neoplasm in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, A; Kim, DY; Kim, JH; Kim, YM; Kim, YT; Lee, SW; Park, JY; Suh, DS | 1 |
| Del Priore, G; Hartzfeld, KM; Hurst, SA | 1 |
| Archer, SG; Barnes, D; Blamey, RW; Eliopoulos, A; Ellis, IO; Nicholson, RI; Robertson, JF; Spandidos, D | 1 |
3 other study(ies) available for megestrol acetate and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Continued medical treatment for persistent early endometrial cancer in young women.
Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Biopsy; Carcinoma, Endometrioid; Disease-Free Survival; Drug Administration Schedule; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Female; Fertility Preservation; Follow-Up Studies; Humans; Intrauterine Devices; Levonorgestrel; Magnetic Resonance Imaging; Medroxyprogesterone Acetate; Megestrol Acetate; Myometrium; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Prognosis; Retrospective Studies; Time Factors; Treatment Failure; Treatment Outcome; Ultrasonography | 2021 |
Occult myometrial recurrence after progesterone therapy to preserve fertility in a young patient with endometrial cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Dilatation and Curettage; Endometrial Neoplasms; Female; Fertility; Humans; Hysterectomy, Vaginal; Hysteroscopy; Infertility, Female; Laparoscopy; Magnetic Resonance Imaging; Megestrol Acetate; Myometrium; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovariectomy; Pregnancy; Progestins; Quality of Life; Reproductive Techniques, Assisted; Surrogate Mothers; Treatment Outcome | 2008 |
Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Breast Neoplasms; ErbB Receptors; Estrogen Antagonists; Female; Gene Expression Regulation, Neoplastic; Goserelin; Humans; Ki-67 Antigen; Life Tables; Megestrol; Megestrol Acetate; Menopause; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Nuclear Proteins; Proportional Hazards Models; Proto-Oncogene Proteins p21(ras); Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Treatment Outcome; Tumor Suppressor Protein p53 | 1995 |